Tissue Regenix Group plc

Tissue Regenix Group plc, established in 2006 and headquartered in Garforth, United Kingdom, is a medical technology enterprise dedicated to advancing the fields of tissue engineering and regenerative medicine. Operating across the United States and international markets, the company develops and commercializes sophisticated platform technologies. Its operations are organized into BioSurgery, Orthopaedics & Dental, and GBM-V & Cardiac divisions. Tissue Regenix's flagship dCELL technology involves a soft tissue decellularization process, which meticulously removes DNA and cellular material from animal and human tissues to facilitate the repair of diseased or injured body parts. Complementing this is BioRinse technology, a natural bone filler designed to stimulate and promote native bone growth through its osteoinductive properties. The company's diverse product portfolio includes DermaPure, a decellularized dermal allograft used for strengthening, repairing, and replacing compromised skin tissue, and SurgiPure XD, a decellularized porcine dermal matrix for mending hernias and body wall defects. For orthopedic applications, Tissue Regenix offers OrthoPure XT, a regenerative scaffold that allows damaged tissue to repopulate with the patient's own cells, alongside various osteoinductive bone matrices such as ConCelltrate 100 and MatrixCellect 100 DBM. Other notable products include Matrix IQ Dermis, a human-derived dermal graft engineered for revascularization and tissue repair, and Matrix OI FlexIt, a flexible demineralized cortical allograft bone sheet. The company also offers DentalFix, a mineralized particulate allograft designed to leverage the osteoconductive properties of natural bone. Its extensive product line further encompasses CardioPure solutions, Matrix OI 100 DBM for non-structural bone-grafting, Matrix OI Strips and Blocks as stem cell containment scaffolds, AmnioWorks for applications in ophthalmology and wound covering, and a variety of specialized sports medicine products.

Tissue Regenix Group plc trades as TRX.L on LSE. The company is classified in Healthcare / Biotechnology and reports in GBP.

The current profile places the business in Biotechnology. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows £28.65M of revenue and -£713,000 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Tissue Regenix Group plc can be compared against peers such as Chill Brands Group PLC, Cizzle Biotechnology Holdings Plc, CRISM Therapeutics Corporation, MyHealthChecked PLC, N4 Pharma Plc, Oxford BioDynamics Plc.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £5.16M, beta of 0.39, and return on equity of -2.4%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

TRX.L currently shows total debt of £10.46M and beta of 0.39. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.tissueregenix.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.